Zobrazit v EDS

The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary

Uloženo v:
Podrobná bibliografie
Název: The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary
Autoři: Kopetz, Scott, Yoshino, Takayuki, Van Cutsem, Eric, Eng, Cathy, Kim, Tae Won, Wasan, Harpreet Singh, Desai, Jayesh, Ciardiello, Fortunato, Yaeger, Rona, Maughan, Timothy S., Beyzarov, Elena, Zhang, Xiaoxi, Ferrier, Graham, Zhang, Xiaosong, Tabernero, Josep
Přispěvatelé: Institut Català de la Salut, [Kopetz S] University of Texas MD Anderson Cancer Center, Houston, TX, USA. [Yoshino T] National Cancer Center Hospital East, Kashiwa, Japan. [Van Cutsem E] University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Eng C] Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. [Kim TW] Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Wasan HS] Hammersmith Hospital, Division of Cancer, Imperial College London, London, UK. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic – Central University of Catalonia, Vic, Spain, Vall d'Hebron Barcelona Hospital Campus
Zdroj: Future Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Informace o vydavateli: Informa UK Limited, 2025.
Rok vydání: 2025
Témata: FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, Otros calificadores::Otros calificadores::/uso terapéutico, Quimioteràpia combinada, Còlon - Càncer - Tractament, Anomalies cromosòmiques, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, Recte - Càncer - Tractament, Plain Language Summary of Publication
Popis: What is this summary about? BRAF V600E-mutant metastatic colorectal cancer is difficult to treat as people often do not respond to standard of care treatment and their cancer gets worse. The BREAKWATER study looked at whether encorafenib plus cetuximab with mFOLFOX6 was a better treatment than standard of care to treat this disease. What were the results? More participants in the encorafenib plus cetuximab with mFOLFOX6 group had their tumor shrink after treatment than those in the standard of care group (61% versus 40%). Participants in the encorafenib plus cetuximab and mFOLFOX6 group might live longer after starting treatment than those in the standard of care group. The side effects reported were expected by researchers. What do the results mean? Encorafenib plus cetuximab and mFOLFOX6 is the new standard of care for this cancer.
Druh dokumentu: Article
Other literature type
Popis souboru: application/pdf
Jazyk: English
ISSN: 1744-8301
1479-6694
DOI: 10.1080/14796694.2025.2491290
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40391894
http://hdl.handle.net/11351/13399
Rights: CC BY NC ND
URL: http://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (http://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
Přístupové číslo: edsair.doi.dedup.....9b64c60318c5ef25c57ff57fb0afa6c5
Databáze: OpenAIRE
Popis
Abstrakt:What is this summary about? BRAF V600E-mutant metastatic colorectal cancer is difficult to treat as people often do not respond to standard of care treatment and their cancer gets worse. The BREAKWATER study looked at whether encorafenib plus cetuximab with mFOLFOX6 was a better treatment than standard of care to treat this disease. What were the results? More participants in the encorafenib plus cetuximab with mFOLFOX6 group had their tumor shrink after treatment than those in the standard of care group (61% versus 40%). Participants in the encorafenib plus cetuximab and mFOLFOX6 group might live longer after starting treatment than those in the standard of care group. The side effects reported were expected by researchers. What do the results mean? Encorafenib plus cetuximab and mFOLFOX6 is the new standard of care for this cancer.
ISSN:17448301
14796694
DOI:10.1080/14796694.2025.2491290